No Data
Zhejiang Jolly Pharmaceutical (300181): Wuling series continues to grow significantly, Bailing Capsules are expected to take over.
Focusing on the field of pharmaceutical mushrooms, the Ulmus series is the main driver of growth, and new products are ready to be launched. The company has mastered the industrial production technology of medicinal mushroom Ulmus, successfully developed multiple new varieties of traditional chinese medicine, and has gradually developed finished pharmaceutical products, chinese herbal pieces, and chinese medicine as a whole.
Express News | The latest research route map of institutions has been released, with Chow Tai Seng being the most focused.
Jolly Pharmaceutical to Take Controlling Stake in Lingyi Biotech in Cooperation Deal; Shares Up 3%
Express News | Zhejiang Jolly Pharmaceutical: Signed a global strategy cooperation framework agreement.
Zhejiang Jolly Pharmaceutical (300181): Bright performance in the third quarter report, stock-based incentives demonstrate the company's confidence in development.
Key Points: The performance in the third quarter is impressive, with a continued positive trend in performance. In the first three quarters of 2024, the company achieved revenue of 2.045 billion yuan, a year-on-year increase of 39.59%; achieved a net income attributable to the parent company of 0.421 billion yuan, a year-on-year increase of 46.9.
Zuoli Pharmaceuticals: third quarter report 2024
